OCGN Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Ocugen, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.72 |
52 Week High | US$2.11 |
52 Week Low | US$0.34 |
Beta | 3.8 |
1 Month Change | 38.71% |
3 Month Change | 72.59% |
1 Year Change | 268.39% |
3 Year Change | -77.55% |
5 Year Change | n/a |
Change since IPO | -39.65% |
Recent News & Updates
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Where Will Ocugen Stock Be In 5 Years?
Apr 27Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course
Feb 24Shareholder Returns
OCGN | US Biotechs | US Market | |
---|---|---|---|
7D | -12.2% | 0.07% | -0.2% |
1Y | 268.4% | 6.9% | 28.2% |
Return vs Industry: OCGN exceeded the US Biotechs industry which returned 6.9% over the past year.
Return vs Market: OCGN exceeded the US Market which returned 28.2% over the past year.
Price Volatility
OCGN volatility | |
---|---|
OCGN Average Weekly Movement | 19.3% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: OCGN's share price has been volatile over the past 3 months.
Volatility Over Time: OCGN's weekly volatility has increased from 14% to 19% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 65 | Shankar Musunuri | www.ocugen.com |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
Ocugen, Inc. Fundamentals Summary
OCGN fundamental statistics | |
---|---|
Market cap | US$476.05m |
Earnings (TTM) | -US$57.68m |
Revenue (TTM) | US$6.61m |
67.0x
P/S Ratio-7.7x
P/E RatioIs OCGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OCGN income statement (TTM) | |
---|---|
Revenue | US$6.61m |
Cost of Revenue | US$39.57m |
Gross Profit | -US$32.97m |
Other Expenses | US$24.71m |
Earnings | -US$57.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.22 |
Gross Margin | -498.96% |
Net Profit Margin | -872.95% |
Debt/Equity Ratio | 9.3% |
How did OCGN perform over the long term?
See historical performance and comparison